-

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences:

Jefferies 2021 Virtual Healthcare Conference
Fireside Chat Presentation: Wednesday, June 2, 2021 at 1:30 p.m. Eastern Time

Goldman Sachs 42nd Annual Global Healthcare Conference
Fireside Chat Presentation: Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time

These conferences will be held virtually. Live webcasts of the presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

Contacts

Media Contact:
Acadia Pharmaceuticals Inc.
Eric Endicott
(858) 914-7161
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Acadia Pharmaceuticals Inc.

NASDAQ:ACAD

Release Versions

Contacts

Media Contact:
Acadia Pharmaceuticals Inc.
Eric Endicott
(858) 914-7161
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com

More News From Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) during an oral presentation at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. Building on previously announced topline results, new analyses provided further evidence of a consistent efficacy signal with once...

Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the treatment of Rett syndrome. Under the terms of the agreement, KYORIN will be responsible for leading the commercialization of DAYBUE STIX in Japan and the related regulatory activities on behalf of Acad...

Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware’s May 2025 decision upholding Acadia’s U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation. “We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which t...
Back to Newsroom